Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Earnshaw

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|June 24, 2016
A Methodological Review of US Budget-Impact Models for New DrugsJosephine Mauskopf, Stephanie Earnshaw
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Budget impact analysis: review of the state of the artJosephine A Mauskopf, Stephanie Earnshaw, C Daniel Mullins
Journal of Managed Care & Specialty Pharmacy|May 26, 2018
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health PlanJonathan Graham, Stephanie Earnshaw, Kate Burslem, et al.
Journal of General Internal Medicine|May 18, 2013
Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menMichael Pignone, Stephanie Earnshaw, Cheryl McDade, et al.
Annals of Internal Medicine|March 8, 2006
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysisMichael Pignone, Stephanie Earnshaw, Jeffrey A Tice, et al.
Archives of Internal Medicine|February 14, 2007
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysisMichael Pignone, Stephanie Earnshaw, Mark J Pletcher, et al.
Journal of Managed Care Pharmacy : JMCP|April 5, 2007
Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical dataChristopher Bell, Jonathan Graham, Stephanie Earnshaw, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
Journal of Neurotrauma|October 21, 2022
Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care SettingLouise Zimmer, Cheryl McDade, Hadi Beyhaghi, et al.
Circulation. Cardiovascular Quality and Outcomes|March 13, 2014
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysisMark J Pletcher, Michael Pignone, Stephanie Earnshaw, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|June 24, 2016
A Methodological Review of US Budget-Impact Models for New DrugsJosephine Mauskopf, Stephanie Earnshaw
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Budget impact analysis: review of the state of the artJosephine A Mauskopf, Stephanie Earnshaw, C Daniel Mullins
Journal of Managed Care & Specialty Pharmacy|May 26, 2018
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health PlanJonathan Graham, Stephanie Earnshaw, Kate Burslem, et al.
Journal of General Internal Medicine|May 18, 2013
Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in menMichael Pignone, Stephanie Earnshaw, Cheryl McDade, et al.
Annals of Internal Medicine|March 8, 2006
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysisMichael Pignone, Stephanie Earnshaw, Jeffrey A Tice, et al.
Archives of Internal Medicine|February 14, 2007
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysisMichael Pignone, Stephanie Earnshaw, Mark J Pletcher, et al.
Journal of Managed Care Pharmacy : JMCP|April 5, 2007
Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical dataChristopher Bell, Jonathan Graham, Stephanie Earnshaw, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
Journal of Neurotrauma|October 21, 2022
Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care SettingLouise Zimmer, Cheryl McDade, Hadi Beyhaghi, et al.
Circulation. Cardiovascular Quality and Outcomes|March 13, 2014
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysisMark J Pletcher, Michael Pignone, Stephanie Earnshaw, et al.
Pageof 2